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Background: The majority of estrogen receptor-positive (ERα+) breast cancers respond to endocrine therapies.
However, resistance to endocrine therapies is common in 30% of cases, which may be due to altered ERα signaling
and/or enhanced plasticity of cancer cells leading to breast cancer subtype conversion. The mechanisms leading to
enhanced plasticity of ERα-positive cancer cells are unknown.
Methods: We used short hairpin (sh)RNA and/or the CRISPR/Cas9 system to knockdown the expression of the
dependence receptor UNC5A in ERα+ MCF7 and T-47D cell lines. RNA-seq, quantitative reverse transcription
polymerase chain reaction, chromatin immunoprecipitation, and Western blotting were used to measure the effect
of UNC5A knockdown on basal and estradiol (E2)-regulated gene expression. Mammosphere assay, flow cytometry,
and immunofluorescence were used to determine the role of UNC5A in restricting plasticity. Xenograft models
were used to measure the effect of UNC5A knockdown on tumor growth and metastasis. Tissue microarray and
immunohistochemistry were utilized to determine the prognostic value of UNC5A in breast cancer. Log-rank test,
one-way, and two-way analysis of variance (ANOVA) were used for statistical analyses.
Results: Knockdown of the E2-inducible UNC5A resulted in altered basal gene expression affecting plasma
membrane integrity and ERα signaling, as evident from ligand-independent activity of ERα, altered turnover of
phosphorylated ERα, unique E2-dependent expression of genes effecting histone demethylase activity, enhanced
upregulation of E2-inducible genes such as BCL2, and E2-independent tumorigenesis accompanied by multiorgan
metastases. UNC5A depletion led to the appearance of a luminal/basal hybrid phenotype supported by elevated
expression of basal/stem cell-enriched ΔNp63, CD44, CD49f, epidermal growth factor receptor (EGFR), and the
lymphatic vessel permeability factor NTN4, but lower expression of luminal/alveolar differentiation-associated ELF5
while maintaining functional ERα. In addition, UNC5A-depleted cells acquired bipotent luminal progenitor
characteristics based on KRT14+/KRT19+ and CD49f+/EpCAM+ phenotype. Consistent with in vitro results, UNC5A
expression negatively correlated with EGFR expression in breast tumors, and lower expression of UNC5A, particularly
in ERα+/PR+/HER2− tumors, was associated with poor outcome.
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Conclusion: These studies reveal an unexpected role of the axon guidance receptor UNC5A in fine-tuning ERα and
EGFR signaling and the luminal progenitor status of hormone-sensitive breast cancers. Furthermore, UNC5A
knockdown cells provide an ideal model system to investigate metastasis of ERα+ breast cancers.
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The luminal subtypes that express the estrogen receptor
(ER)α represent approximately 70% of breast cancers, and
the majority of these tumors respond to endocrine therapy
[1]. However, resistance to endocrine therapy resulting in
relapse is seen in approximately 30% of patients [1]. ERα+
breast cancers are heterogeneous with at least two
subtypes, luminal A and luminal B [2]. Luminal A
tumors are estradiol (E2)-dependent and responsive to
antiestrogens, whereas luminal B tumors display either
intrinsic or acquired resistance to antiestrogens with an
outcome almost similar to triple negative breast cancers
(TNBCs) [3]. A subgroup of luminal A tumors, particularly
those that have metastasized despite expressing luminal A
biomarkers (ERα and progesterone receptor (PR)), do not
respond to antiestrogen therapies and approximately 55%
of these metastases have converted to a different subtype
through an unknown mechanism [4].
Multiple mechanisms of antiestrogen resistance have
been documented [5]. Most of the prior work focused on
mechanisms that confer E2-independent activity to ERα,
including kinases that phosphorylate ERα, co-activator
molecules that enhance ERα activity, pioneer factors that
govern chromatin binding of ERα, and growth factor re-
ceptor–ERα crosstalk [6–8]. However, to our knowledge,
there have been limited attempts to decipher negative
regulatory loops that may restrict ERα signaling subse-
quent to ligand-activated induction and deregulation of
these negative regulatory loops leading to prolonged/
sustained activation of ERα.
To identify luminal cell-expressed genes that may play a
role in restricting E2-dependent proliferation, we scanned
gene expression array datasets for E2-inducible genes with
ERα binding sites and that have a growth inhibitory activity
[9]. From this search, we focused on the dependence recep-
tor (DR) pathways for their potential role in a negative feed-
back loop. Under physiological conditions, unliganded DRs
elicit cell death and/or growth inhibition but elicit cell sur-
vival and proliferation when coupled with their ligands such
as Netrin-1 (NTN1) [10]. DRs are direct transcriptional tar-
gets of p53 and integral to p53-dependent apoptotic path-
ways, particularly in the absence of ligands [11]. NTN1
belongs to the evolutionary conserved netrin family se-
creted proteins and is well characterized for its role in the
nervous system [12]. Both netrins and DRs also play crucial
roles in other systems, including development of themammary gland, inner ear, lungs, and pancreas [12, 13].
Loss of heterozygosity and homozygous deletion of DRs
and upregulation of netrins are observed in a variety of can-
cers including breast cancer [11, 13]. These aberrations in
DR–netrin pathways are believed to confer resistance to
p53-dependent apoptosis and enhance proliferation of
cancer cells.
In the present study, we show that UNC5A is an E2-
inducible gene. Knockdown of UNC5A in ERα+/PR+ cells
resulted in defective turnover of phosphorylated ERα,
enhanced E2 signaling, cell proliferation, and tumorigenesis
independent of E2 supplementation accompanied with
multiorgan metastases in xenograft models. Furthermore,
UNC5A knockdown cells acquired a hybrid basal/luminal
phenotype including elevated expression of epidermal
growth factor receptor (EGFR). Thus, UNC5A could serve
as a negative feedback molecule in ERα signaling, the
deregulation of which could lead to breast cancer
progression through enhanced plasticity.
Methods
Immunohistochemistry of tissue microarray (TMA)
Tissue samples were collected with Indiana University
Institutional Review Board approval, informed patient
consent, and HIPAA compliance. UNC5A and EGFR
immunostaining was performed at the CLIA certified
Indiana University Health Pathology Laboratory and scor-
ing has been described previously [14]. H scores were cal-
culated using stain intensity (0 to 3) multiplied by percent
positive pixels (for UNC5A) or a formula based on stain
intensity and number of weak, moderate, or strong posi-
tive pixels (for EGFR). For subjects with multiple tumor
samples, only those with the highest H score were consid-
ered. Statistical analysis was performed on samples from
221 breast cancer patients, but only 196 patient samples
(89%) had UNC5A values available. The log-rank test was
used to compare patient and tumor variables between
those with UNC5A H scores versus those without. The
correlations between UNC5A and EGFR were determined
by Spearman’s correlation coefficient. For modeling the
outcomes of overall survival and disease-free survival, the
multivariate covariates used in the multivariate models
from the individual reports for EGFR and UNC5A were
included. Additionally, the H score information for EGFR
and UNC5A were handled in three ways. First, the EGFR
and UNC5A were dichotomized using the same optimal
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the EGFR and UNC5A were dichotomized using their in-
dividual medians and cut-points. Finally, the continuous
values were used in the models. Since EGFR was not
linear, the natural log of EGFR was used in the models.
For the models with continuous values, hazard ratios were
calculated at the 25th, 50th, and 75th percentile of EGFR.
Subgroup analyses were performed where the number of
patients available was sufficient.
Cell lines
MCF7 and T-47D cells were obtained from American
Tissue Culture Collection and cultured in minimum es-
sential media (MEM) media as described previously [15].
TMCF7 cells correspond to cell lines derived from tu-
mors developed in the mammary fat pad of nude mice
implanted with MCF7 cells [16]. Cell lines were authen-
ticated using Short Tandem Repeat Profiling Systems for
cell line identification by a commercial vendor (DNA-
center.com) in August 2012 and cell lines recreated
from xenograft tumors were authenticated by Genetica
(Burlington, NC, USA).
Short hairpin (sh)RNA and CRISPR constructs
The human shRNA lentiviral transduction particles for
sh5-UNC5A and pLKO.1-puro vector control plasmids
(sh-Control) were purchased from Sigma (cat. nos.
SHCLNV-NM_133369 and SHC 001, respectively). The
lentivector for sh2-UNC5A was obtained from Applied
Biological Materials (cat. no. i026703g). CRISPR plas-
mids to target UNC5A were obtained from Sigma-
Aldrich (HS0000509914).
Western blotting
Treatments consisted vehicle, heregulin-β1 (HRG-β1,
R&D systems), E2, 4-hydroxy-tamoxifen (OHT), or
ICI-182,780 (Sigma-Aldrich). The immunoblotting has
been previously described [17] and details of antibodies
are provided in Additional file 1. Although the majority of
immunoblots were reprobed with antibodies against
ACTB (β-actin) as a loading control, only representative
data per batch of cell lysates are shown.
RNA-seq and quantitative reverse transcription
polymerase chain reaction (qRT-PCR)
cDNA was synthesized from 1 to 2 μg of total RNA
using the cDNA Synthesis Kit (Bio-Rad). qRT-PCR in
duplicates from at least two biological replicates was
performed with either Sybr-Green or TaqMan Universal
PCR master mix and transcripts were analyzed in
StepOnePlus and TaqMan 7900HT instruments (Applied
Biosystems) with β-ACTIN as the normalization control.
Fold-change was calculated by the ΔΔCt method, whereas
statistical analysis was performed on ΔCt values. Primers(Integrated DNATechnologies) and TaqMan probe details
are shown in Additional file 1. RNA-seq of sh-Control and
sh5-UNC5A cells treated for 3 h with vehicle or E2 was
performed in triplicate as previously described [18], and
raw sequencing data have been submitted to the gene ex-
pression omnibus (GEO; accession number GSE89700).
We used STAR RNA-Seq aligner to map all sequence
libraries to the human genome (UCSC hg19) [19]
followed by the assignment of uniquely mapped reads to
individual genes based on annotation of hg19 refGene
by featureCounts [20]. After trimmed mean of M values
(TMM) normalization, gene expression profiling was
summarized on the base-2 logarithmic scale. Genes with
an average expression level lower than 1 for all pheno-
types in MCF7 and T-47D cells, respectively, were ex-
cluded for further analysis. Differential expression (DE)
analysis was performed using edgeR [21, 22] for special
group comparisons in the study. All p values were cor-
rected by multiple testing false discovery rate (FDR)
adjustments. Genes with FDR < 0.05 and absolute value
of fold change (FC) larger than 2 were determined as
differentially expressed genes (DEGs).
Gene function enrichment analysis was performed using
DAVID (http://david.abcc.ncifcrf.gov/home.jsp v6.8) [23, 24].
Significantly overrepresented gene ontology (GO) terms
were selected if their q values (p values after FDR multiple
test correction) were less than 0.05.
Promoter luciferase assay
Cells transfected with luciferase constructs were allowed
to grow overnight in charcoal-dextran treated fetal calf
serum (CCS) containing media followed by a 12-h E2
treatment. The Dual-Luciferase® Reporter assay (Promega)
was performed according to the manufacturer’s protocol.
Chromatin immunoprecipitation (ChIP) assay
ChIP assays for ERα binding on UNC5A and BCL2 were
performed under vehicle or E2 treatment for 45 min and
2 h as described previously [9].
Cell proliferation and mammosphere assays
After 24-h plating in regular media, the media was chan-
ged to CCS-containing media for 3 days and cells were
treated with the indicated drug combinations. Cell
proliferation was determined using the bromodeoxyuridine-
incorporation enzyme-linked immunosorbent assay (ELISA)
kit from Calbiochem after 5–6 days of plating with one
media/drug change. Mammosphere assays with 5000 cells
were performed as described previously [25].
Immunofluorescence
Cells grown on 35-mm glass-bottom culture dishes were
fixed with 4% (w/v) paraformaldehyde for 10 min and
permeabilized in phosphate-buffered saline (PBS) containing
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(Gibco), and 1% (w/v) bovine serum albumin (Sigma-
Aldrich) for 1 h. Cells were incubated with primary anti-
bodies (Additional file 1) diluted in Dako antibody diluent
(Dako; Agilent Technologies) for 90 min followed by 1-h
incubation with the Alexa Fluor® 488 and 555 conjugated
secondary antibodies (ThermoFisher Scientific). Nuclei
was counterstained with Hoechst® 33,342.
Flow cytometry
Cells were stained with the indicated antibodies (Additional
file 1) and analyzed in a LSR4 custom-made flow cytometer
(BD Biosciences) as described previously [26].
Xenograft studies
The Indiana University Animal Care and Use Committee
approved the use of animals in this study and all proce-
dures were performed as per NIH guidelines. sh-Control,
sh2-UNC5A, and sh5-UNC5A TMCF7 cells (2 × 106 in
100 μl serum-free HBSS) were implanted into the mam-
mary fat pad of 7-week-old female nude mice with or
without a 60-day slow-release E2 pellet. Tumor growth
was measured weekly and tumor volume was calculated
as described previously [16]. After 12 weeks, the lungs
and primary tumors were collected and processed for
hematoxylin and eosin (H&E) and PECAM1 (CD31)
staining. The whole slide digital imaging system of
Aperio (ScanScope CS) was used for imaging of
PECAM1-stained tumors. For the metastatic model,
mice were inoculated with 2 × 105 TMCF7 cells into the
left cardiac ventricle. Ovaries, spleen, and adrenal glands
were collected within 17 weeks and processed as
described above.
Statistical analysis
Statistical analyses were performed in GraphPad Prism®
(6.02 version) or Statistical Analysis System (SAS; ver-
sion 9.4) software with p < 0.05 considered as significant.
Results
UNC5A is a luminal cell-enriched gene and is E2 inducible
To determine E2-inducible signaling molecules that may
dampen the E2 response or gene-specific E2 regulation
and that are expressed at higher levels in luminal breast
cancers compared with TNBCs, we first searched our
previous microarray data of E2-regulated genes in MCF7
cells for known growth suppressive roles and then
determined whether E2 directly regulated their expres-
sion by integrating E2-inducible gene expression with
ERα ChIP-on-chip and ChIP-seq datasets. UNC5A
suited these criteria as its expression was E2 inducible
and ERα binding sites for this gene was detectable in
ChIP-on-chip and ChIP-seq datasets [9, 27] (Fig. 1a).
Furthermore, in 11 out of 12 studies in publicly availableNuclear Receptor Signaling Atlas web resources showed
2- to 35-fold E2-inducible expression of UNC5A in
MCF7 cells, uterus, and vagina (Additional file 2). We
further confirmed E2-inducible expression of UNC5A in
MCF7 cells by qRT-PCR (Fig. 1b) and Western blotting
(see below), although induction at mRNA levels in our
MCF7 cells was modest. Interestingly, the antiestrogen
tamoxifen (OHT) failed to overcome the effect of E2 on
UNC5A levels (Fig. 1b) suggesting unique effects of E2 on
the expression of UNC5A. We used ChIP assay to verify
ERα binding to one of the ERα binding sites (Fig. 1c). R2
Genomic and Visualization Platform (http://r2.amc.nl)
analyses revealed a positive correlation between UNC5A
and ESR1 mRNA levels in breast cancer cell lines (Fig.
1d). Also, analyses of The Cancer Genome Atlas (TCGA)
dataset for the relationship between UNC5A expression
and breast cancer subtypes using the UALCAN program
[28] revealed highest UNC5A expression in luminal breast
cancers, which are usually ERα-positive, compared with
TNBCs (Fig. 1e). In contrast, NTN1 expression was
higher in TNBCs compared with normal breast or luminal
breast cancers (Fig. 1f).
Low UNC5A expression in primary breast cancers is
associated with poor outcome
To obtain additional support for our hypothesis that a
protein that attenuates ERα signaling has prognostic
relevance, we performed immunohistochemical analyses
of UNC5A in our previously described breast TMA in
which 196 out of 221 tumors had measurable UNC5A
expression [14] (Additional file 3). A representative
staining pattern of UNC5A in breast tumor is shown in
Fig. 2a. Tumor cells were moderate in staining in many
of the cases with little to no background staining in the
other tissues in the core (vascular endothelial cells,
smooth muscle cells, fibroblasts, macrophages, and/or
scattered lymphocytes infiltrating the tumor region). In
both univariate and multivariate analyses, low UNC5A H
score was associated with poor overall survival (Fig. 2b
and Additional file 4). In subgroup analyses, in ER+/PR+/
HER2−, lower UNC5A H score showed a trend of poor
overall survival (p = 0.055) (Fig. 2c). UNC5A had no
prognostic relevance when tumors were subgrouped
broadly into ER+ or ER− subgroups (Fig. 2d, e). Thus,
UNC5A is a potential biomarker of outcome in a
subgroup of breast cancer patients whose tumors express
luminal A markers.
UNC5A knockdown results in enhanced ERα signaling
To model low UNC5A levels in cells with intact ERα-
dependent signaling, we created shRNA-UNC5A MCF7
and T-47D cells, which express ERα and PR at different
levels (Fig. 3a, b). MCF7 cells are more responsive to E2
than T-47D cells and, therefore, most of the experiments
Fig. 1 UNC5A is an estradiol (E2)-inducible gene. a Estrogen receptor (ER)α binding sites on UNC5A genomic region. Chromatin immunoprecipitation
(ChIP)-seq datasets in MCF7 cells from Welboren et al. [27] (ER_minus ligand, ER-E2, ER-tamoxifen) and ChIP-on-chip datasets in MCF7 and MCF7 cells
overexpressing constitutively active AKT from Bhat-Nakshatri et al. [9] were used to identify ERα binding sites on UNC5A genomic regions. Four ERα
binding sites on chromosome 5 (hg18/human) are indicated on the top with genomic coordinates 176,169,194–176,169,471, 176,173,985–176,174,876,
176,206,209–176,206,749 and 176,229,374–176,230,036, respectively. b The effect of E2 (10−10 M), tamoxifen (OHT; 1 μM), or both on UNC5A expression
in MCF7 cells. Cells were treated for 3 h and UNC5A levels were measured by qRT-PCR. Bar graphs represent mean ± SEM of fold change relative to
vehicle control (n = 3). c ChIP assay confirms binding of ERα to UNC5A regulatory regions (second ERα binding site from the left). MCF7 cells were
treated with vehicle or E2 (10−8 M) for 45 min and 2 h. ERα DNA binding levels are presented as mean ± SEM of non-normalized values relative to the
vehicle sh-Control (n = 2). d mRNA levels of ESR1 and UNC5A show positive correlation in breast cancer cell lines. R2 Genomics Analysis and Visualization
Platform (http://r2.amc.nl) tool was used to obtain these results. e UNC5A mRNA levels in different subtypes of breast cancers in the TCGA dataset. Data
were obtained using the public database UALCAN [28]. f NTN1 mRNA levels in different subtypes of breast cancers in the TCGA dataset. TNBC, triple
negative breast cancer
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periments in T-47D cells. UNC5A knockdown did not
have an effect on ERα levels and the receptor underwent
activation-coupled degradation upon E2 treatment in
both sh-Control and sh-UNC5A cells (Fig. 3a, b). Note
that E2 increased UNC5A protein in sh-Control but not
in sh-UNC5A MCF7 cells (Fig. 3a). We note that this is
the only commercially available antibody (Abcam,
ab81165) that recognized protein of expected size butshowed variability in potency between batches. In transi-
ent transfection assay, estrogen response element (ERE)-
driven luciferase-reporter gene showed elevated activity in
vehicle-treated sh-UNC5A cells compared with sh-Control
cells (Fig. 3c). In T-47D cells, which express higher levels
of PR than MCF7 cells [29], UNC5A knockdown en-
hanced E2-inducible expression of PGR (Fig. 3d). In both
MCF7 and T-47D cells, UNC5A knockdown substantially
increased both basal (vehicle-treated) and, consequently,
Fig. 2 Low UNC5A in breast tumors correlates with poor overall survival of breast cancer patients. a Representative UNC5A staining pattern in
breast tumors with high or low expression (scale bars = 200 μm). b Kaplan-Meier survival curves comparing overall survival of breast cancer
patients with high (blue line) against low (red line) expression of UNC5A in tumors. Datasets were analyzed by log rank test from n = 196 patients.
c Kaplan-Meier survival analysis of ER+/PR+/HER− breast cancer patients according to the expression of UNC5A in tumors (p = 0.055) (n = 98).
d Kaplan-Meier survival analysis of estrogen receptor (ER)α+ breast cancer patients according to the expression of UNC5A in tumors (n = 144).
e Kaplan-Meier survival analysis of ERα− breast cancer patients according to the expression of UNC5A in tumors (n = 44). PR, progesterone receptor
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(Fig. 3e, f ). The enhanced BCL2 expression in sh-
UNC5A cells correlated with increased E2-independent
binding of ERα to the enhancer element of BCL2 to which
ERα and JMJD3 bind to create a poised chromatin [30]
(Fig. 3g). To determine whether enhanced ERα activity in
UNC5A-knockdown cells is due to altered phosphoryl-
ation of ERα, we used phospho-specific antibodies to de-
termine the levels of ERα phosphorylated at S118 and
S167. Phosphorylation of ERα at these residues is known
to confer ligand-independent activity to the receptor [1].
Although we did not find any differences in basal phos-
phorylation status between sh-Control and sh-UNC5A
cells, phosphorylated ERα underwent ligand-coupled deg-
radation in sh-Control cells but not in sh-UNC5A cells
(Fig. 3h). As a consequence, there was a modest difference
in the rate of degradation of total ERα between clones.These results suggest the need for signaling events down-
stream of UNC5A in turnover of phosphorylated ERα.
To determine whether the above observations of altered
phospho-ERα turnover upon UNC5A knockdown show
any relationship with cell proliferation, we measured cell
proliferation under vehicle control and E2 ±OHT-treated
conditions. In MCF7 cells, sh-UNC5A increased prolifera-
tion under vehicle control, E2-, OHT-, and OHT plus E2-
treated conditions compared with sh-Control to levels
similar to E2-treated sh-Control cells (Fig. 3i, j). Although
OHT reduced E2-inducible proliferation of sh-UNC5A
cells, the overall proliferation rate of these cells under
various treatments remained elevated compared with sh-
Control cells. Collectively, these results suggest that
UNC5A restricts the proliferation of ERα-positive cells.
To investigate whether enhanced the baseline prolifer-
ation of sh-UNC5A cells compared with sh-Control cells
Fig. 3 (See legend on next page.)
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Fig. 3 Estradiol (E2)-regulated gene expression and response in cells on UNC5A knockdown. a UNC5A expression in sh-Control and sh-UNC5A
transfected MCF7 cells (top). sh2-RNA and sh5-RNA target independent sequences of UNC5A. E2-inducible expression of UNC5A protein is evident
in sh-Control but not in sh-UNC5A transfected MCF7 cells. Estrogen receptor (ER)α expression in sh-Control and sh-UNC5A MCF7 cells treated with
or without E2 for 24 h (bottom). b Generation of T-47D cells expressing sh-UNC5A (top). shRNA expressing cells have lower UNC5A transcripts
(mean ± SEM; n = 3). As in MCF7 cells, sh-UNC5A had no effect on ERα protein levels in T-47D cells (bottom). c ERE-luciferase activity in sh-Control
and sh-UNC5A TMCF7 cells. Cells were treated with vehicle or three different concentrations of E2 for 12 h (mean ± SEM; n = 4). Data were
analyzed by two-way ANOVA where the main effects clone and [E2] were considered significant at p < 0.01 and p < 0.001, respectively. Note that
ERE-luciferase activity was higher in sh-UNC5A clones in the absence of E2 treatment, although there was experimental variability. d UNC5A
knockdown increases E2-inducible PGR expression in T-47D cells. Cells were treated with vehicle or E2 for 3 h (n = 4; **p < 0.01). e UNC5A
knockdown leads to increased BCL2 expression. BCL2 mRNA (left) was measured in vehicle and E2-treated (3 h) sh-Control and sh-UNC5A MCF7
cells (***p < 0.001). BCL2 protein levels were measured by Western blotting (right) in cells treated with vehicle, E2 (10−10 M), tamoxifen (OHT;
10−6 M), or an E2 and OHT combination for 24 h. f The effects of UNC5A knockdown on BCL2 expression in T-47D cells. Cells were treated with
vehicle control and E2 for 3 h (mRNA) or 24 h (protein) (**p < 0.01 and ***p < 0.001). g sh-UNC5A enhances ERα binding to ERE-elements of BCL2
in MCF7 cells. ERα binding sites on BCL2 genomic regions identified using ChIP-seq and ChIP-on-chip data are shown in the left. ERα binding to ERE-
elements (right most binding site indicated by a star in the ChIP-seq dataset, genomic coordinates, Chr18; 59,136,368–59,136,898) of BCL2 was verified
by ChIP-qPCR assay (mean ± SEM of non-normalized values relative to vehicle sh-Control; n = 2). ERα binding in vehicle-treated sh-Control cells was set
at 1 and the relative difference in other conditions is shown. h The effect of UNC5A knockdown on phosphorylated ERα. Cells were treated with E2 for
3 h or 6 h and the cell lysates were analyzed for ERα phosphorylated at S118 or S167 and total ERα. While phosphorylated ERα underwent
activation-coupled degradation on E2 treatment in sh-Control cells, phosphorylated ERα was refractory to degradation in sh-UNC5A cells. i
The effect of UNC5A knockdown on proliferation of sh-Control and sh-UNC5A MCF7 cells. Cells were treated for 5 days with vehicle control, E2, OHT, or
E2 + OHT. Data are presented as mean of relative absorbance ± SEM (n = 2, each with six technical replicates) and were analyzed by ANOVA. Bars with
the same character/letters are not significantly different according to Tukey’s test. For example, E2-induced proliferation rate of sh-Control cells is similar
to the proliferation rate of vehicle-treated sh2-UNC5A cells. j The effect of UNC5A knockdown on proliferation of T-47D cells. Assays were performed as
in i and the statistical results are presented as in i
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(Fulvestrant) which degrades ERα. While ICI-182,780 re-
duced E2-induced proliferation of these cells, it had a
minimal effect on baseline proliferation of all cell types
(Additional file 5). These negative results can be
interpreted in two ways: enhanced basal proliferation of
sh-UNC5A cells compared with sh-Control cells is inde-
pendent of ERα, or ERα in sh-UNC5A cells is less sensi-
tive to ICI-182780-mediated degradation. Surprisingly,
although ICI-182,780 caused degradation of total ERα in
sh-Control and sh-UNC5A cells to a similar extent, ICI-
182,780 increased the levels of ERα phosphorylated at
S118 (Additional file 5). This unique effect of ICI-
182,780 on phospho-ERα could explain the lack of its
effects on the baseline proliferation rate of sh-UNC5A
cells. Additional work is needed to clarify the role of
ERα in the baseline proliferation rate of sh-UNC5A cells.
The dramatic effect of UNC5A on BCL2 expression
was puzzling. To ensure that this increase in BCL2 ex-
pression is not due to aberrant integration of shRNAs
into the genome, we used the CRISPR/Cas9 system to
reduce UNC5A expression and selected single cell clones
(Additional file 5). UNC5A protein levels were partially
reduced in these single cell clones with an accompanying
increase in BCL2 expression. Thus, even a modest de-
crease in UNC5A protein levels was sufficient to trigger
BCL2 expression. We also observed stable BCL2 overex-
pression in both UNC5A shRNA and CRISPR clones
cultured for a prolonged time despite these clones
regaining UNC5A protein expression as measured
using the available antibody. Thus, it appears thateven transient knockdown of UNC5A leads to robust/
permanent activation of BCL2, which is similar to
previously reported stable activation of cancer germ-
line genes upon transient knockdown of DNA methyl-
transferase 1 (DNMT1) [31].
Changes in gene expression associated with UNC5A
knockdown
We performed RNA-seq of sh-Control and sh5-UNC5A
MCF7 and T-47D cells treated with vehicle (basal) or E2
for 3 h and did pairwise comparisons to determine the
effect of UNC5A on basal and E2-regulated gene expres-
sion (Fig. 4a). Genes were determined as DEGs for com-
parison if their FDR was < 0.05 and absolute value of
fold change |FC| was > 2 (Fig. 4a and Additional file 6).
Under basal growth conditions, UNC5A knockdown
notably affected the expression of approximately 20%
and 7% of genes in MCF7 and T-47D cells, respectively,
potentially indicating its role in regulating the transcrip-
tional machinery. For example, APOBEC3B, which is in-
tegral to ERα signaling [32], was one of the genes
differentially expressed in sh-UNC5A cells compared
with sh-Control MCF7 and T-47D cells (Additional
file 6). We confirmed elevated expression of APOBEC3B
in sh-UNC5A compared with sh-Control MCF7 cells
(Fig. 4b). Based on the gene functional analysis using
DAVID, genes differentially expressed in UNC5A knock-
down MCF7 and T47-D cells were an integral part of
the plasma membrane and extracellular region (Fig. 4c
and Additional file 7). It is interesting to note that 167
DEGs in MCF7 cells were significantly overrepresented
Fig. 4 The effect of UNC5A knockdown on basal and estradiol (E2)-regulated gene expression in MCF7 and T-47D cells. a Venn diagram showing
the number of differentially expressed genes in UNC5A knockdown MCF7 and T-47D cells compared with sh-Control cells with and without 3 h
E2 treatment. b UNC5A knockdown MCF7 but not T-47D cells express higher levels of APOBEC3B (**p < 0.01 and ***p < 0.001). c Signaling pathways
affected by UNC5A knockdown under vehicle and E2-treated conditions. The number of genes in each of the networks is shown and name of the
genes in each network and fold changes in expression are presented in Additional files 7 and 6, respectively. UNC5A affected mainly basal gene
expression in T-47D cells. The gene set ‘E2 regulation unique in sh-UNC5A MCF7 cells’ corresponds to those genes whose magnitude of E2-regulated
expression differed from sh-Control cells, although these genes may be E2-regulated in both cell types. The gene set ‘E2 regulation exclusively in
sh-UNC5A MCF7 cells’ corresponds to those genes whose expression was E2-regulated only in sh-UNC5A cells. d Heatmap of genes uniquely upregulated
or downregulated by E2 in sh-UNC5A MCF7 cells. E2 did not affect their expression in sh-Control MCF-7 cells. e The effect of UNC5A knockdown on basal
and E2-inducible expression of TFF1 and GREB1. TFF1 and GREB1 expression was measured by qRT-PCR in vehicle, 3-h, and 6-h E2-treated cells. GREB1
expression in 3-h and 6-h E2 treated sh-UNC5A cells was modestly but significantly higher compared with E2-treated sh-Control cells (indicated by *)
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activity (Fig. 4c). UNC5A knockdown also had a signifi-
cant effect on E2-regulated gene expression, particularly
in MCF7 cells. A total of 434 genes were recognized as
undergoing significant changes in gene expression by E2
in sh-UNC5A MCF7 cells, whereas only 21 genes were
identified as DEGs in sh-UNC5A T-47D cells (Fig. 4a
and Additional file 6). In sh-UNC5A MCF7 cells but not
in sh-Control cells, E2-targeted genes were associated
with negative regulation of cell proliferation, extracellu-
lar region, and histone demethylase activity (Fig. 4c). For
example, E2 induced the expression of histone demethy-
lases KDM4B and KDM7A but reduced the levels of
UTY and ARID5B in sh-UNC5A but not in sh-Control
MCF7 cells [33] (Additional file 6). JARID2, which
regulates the polycomb complex and histone methyl-
transferases [34], was E2 inducible in sh-UNC5A but not
in sh-Control MCF7 cells (Additional file 6). Further-
more, we found that 109 out of these 434 genes (Fig. 4d)
were not regulated by E2 in sh-Control MCF7 cells
(FDR > 0.5 and |FC| < 1.15), whereas their expression
was under E2 control in sh-UNC5A MCF7 cells. These
109 genes are associated with positive regulation of gene
expression and affect transcriptional regulation by RNA
polymerase II (Fig. 4c). By contrast, no specific GO func-
tions could be assigned to uniquely E2-regulated genes
in sh-UNC5A T-47D cells. We note that the effect of
UNC5A on E2-regulated genes is gene-specific since sh-
Control and sh-UNC5A MCF7 cells showed similar
levels of E2-regulated expression of TFF1 and only a
modest effect on E2-regulated expression of GREB1, two
commonly used genes to measure E2-inducible genes
(Fig. 4e). Collectively, these results indicate a cell type-
dependent role of UNC5A in controlling basal and E2-
regulated gene expression with potential downstream
effects ranging from plasma membrane composition to
transcriptional output from RNA polymerase II.
UNC5A knockdown results in nonclassical luminal/basal
hybrid gene expression pattern
UNC5A knockdown increased the levels of oncogenic
ΔNp63 isoform mRNA while simultaneously lowering
the expression of tumor suppressive TAp63 isoform [35]
(Fig. 5a, b). TP63 is an E2-repressed gene and ERα failed
to repress ΔNp63 in sh-UNC5A clones with efficient
UNC5A knockdown (sh5-UNC5A clones of MCF7 and
T-47D; Fig. 5a, b). Overall, ΔNp63 levels ± E2 treatment
remained elevated in sh-UNC5A cells compared with sh-
Control cells. RNA-seq studies showed lower expression
of luminal/alveolar differentiation-associated ELF5 but
elevated expression of the pro-oncogenic MECOM (EVI-
1) and lymphangiogenic NTN4 [36–38] in sh-UNC5A
cells compared with sh-Control cells (Additional file 6).
Indeed, ELF5 levels were significantly lower and NTN4levels were higher in sh-UNC5A cells compared with sh-
Control cells (Fig. 5c, d). MECOM protein was undetect-
able in MCF7 cells but elevated in sh-UNC5A T-47D
cells compared with sh-Control cells (Fig. 5e). In
addition, while sh-Control cells expressed mainly KRT19,
sh-UNC5A cells expressed either KRT14, KRT19, or
both KRT14 and KRT19 (basal and luminal cytokeratins,
respectively) [39] (Fig. 5f and Additional file 8). Bipotent
luminal progenitor cells are KRT14 and KRT19 double-
positive [40]. Note that UNC5A knockdown did not re-
sult in the morphologic features of epithelial to mesenchy-
mal transition (EMT), nor did it result in the expression of
EMT-associated genes such as SNAI1, SNAI2, ZEB1, or
ZEB2 (Additional file 6 and data not shown). However, we
observed elevated expression of ITGB6 (Integrin β6) in sh-
UNC5A cells compared with sh-Control cells (Additional
file 6); ITGB6 is pro-oncogenic and is induced during
EMT of colon cancer cells [41].
Since ΔNp63 maintains stem cell phenotype and can-
cer cells with hybrid luminal/basal/mesenchymal charac-
teristics display enhanced cancer stem cell (CSC)
properties [35, 42], we used mammosphere assays and
flow cytometry to characterize sh-Control and sh-
UNC5A MCF7 cells for stemness. While mammospheres
of sh-Control were well organized, sh-UNC5A cells
formed irregular mammospheres (Fig. 5g). In addition,
while sh-Control cells were predominantly CD49f
(ITGA6)−/EPCAM+, a subpopulation of sh-UNC5A cells
showed CD49f+/EPCAM+ phenotype (Fig. 5h). CD49f+/
EPCAM−, CD49f+/EPCAM+, and CD49f−/EPCAM+ cells
display stem/basal, luminal progenitor, and differentiated/
mature features, respectively [43]. Sh-Control cells showed
CD44−/CD24+ non-CSC phenotype whereas sh-UNC5A
cells acquired the features of CSCs as evident from the
presence of CD44+/CD24+ and CD44+/CD24− cells
[44]. Furthermore, sh-UNC5A MCF7 cells expressed
significantly higher levels of stemness-associated SOX2 [45]
(Additional file 6).
UNC5A knockdown results in elevated EGFR expression
and AKT activity
Two of our observations and one prior report prompted
us to investigate whether UNC5A knockdown is associ-
ated with altered activity of EGFR, which could explain
the effects of UNC5A on E2-regulated gene expression.
First, we observed enhanced basal ERE-luciferase activity
in sh-UNC5A cells, suggesting ligand-independent
activity of ERα which typically involves growth factor re-
ceptor–ERα crosstalk [46]. EGFR is forefront in this
crosstalk as it can alter ERα cistrome and ERα-regulated
gene expression [47]. Second, sh-UNC5A cells showed
luminal/basal hybrid phenotype, and EGFR activation is
common in cells with basal phenotype [48]. Third, a re-
cent study showed that NTN1, in the absence of
Fig. 5 (See legend on next page.)
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Fig. 5 UNC5A knockdown results in luminal/basal hybrid and bipotent luminal progenitor phenotype. a ΔNp63 levels are significantly elevated in
sh-UNC5A MCF7 cells. Cells were treated with vehicle or estradiol (E2) for 3 h and qRT-PCR was used to measure ΔNp63 and TAp63 levels (mean ± SEM,
n = 2). Data were analyzed as in Fig. 3e (*p < 0.05, **p < 0.01, and ***p < 0.001). TP63 protein levels in sh-Control and sh-UNC5A MCF7 cells treated with
or without E2 for 24 h are shown on the right. TP63 is expressed as multiple isoforms and there appears to be isoform switching in sh-UNC5A cells
compared with sh-Control cells. b ΔNp63 and TAp63 levels in sh-Control and sh-UNC5A T-47D cells. c sh-UNC5A cells have lower ELF5 mRNA compared
with sh-Control cells. Cells were treated with vehicle or E2 for 3 h and qRT-PCR was used to measure ELF5. d UNC5A knockdown leads to elevated
NTN4. e UNC5A knockdown leads to elevated MECOM (EVI-1) expression in T-47D cells. Although MECOM levels were elevated in MCF7 cells upon
UNC5A knockdown (Additional file 6), proteins were not detected by Western blotting. f UNC5A knockdown T-47D cells express both KRT14 (basal;
green) and KRT19 (luminal; red) while sh-Control T-47D cells express luminal KRT19. Results for TMCF7 cells are shown in Additional file 8. g sh-UNC5A
MCF7 cells form irregularly shaped mammospheres. h UNC5A knockdown MCF7 cells display phenotypic characteristics similar to luminal progenitor
(CD49f+/EpCAM+)/cancer stem cells (CD44+/CD24−) compared with sh-Control cells. A histogram displaying CD49f and CD44 expression in different
cell types is depicted on the right
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[49]. We first measured EGFR levels in sh-Control and
UNC5A knockdown cells. EGFR protein but not mRNA
levels were significantly higher in sh-UNC5A cells com-
pared with sh-Control cells (Fig. 6a and data not shown).
AKT and ERK are the two major kinases activated down-
stream of EGFR that can increase ligand-independent
activity of ERα [1]. We determined whether UNC5A
knockdown had an effect on vehicle, E2-regulated, and
HRGβ1-induced activation of these kinases. sh-UNC5A
cells showed robust activation of AKT as measured by
pAKT-S473 levels but not ERK (Fig. 6b). We recently re-
ported that AKT1 but not AKT2 is active in MCF7 cells
[17]. Immunoblotting using isoform-specific phospho-
antibodies showed upregulation of pAKT1 but not pAKT2
in sh-UNC5A cells compared with sh-Control cells
(Fig. 6c). These results indicate a negative relationship
between EGFR and UNC5A expression in cell line models.
Similarly, UNC5A and EGFR expression showed negative
correlation in breast tumor samples when the analyses in-
cluded all samples or only ER+ samples (Fig. 6d).
We next investigated the role of ERα in negative crosstalk
between UNC5A and EGFR/TP63. Treatment of cells with
ICI-182,780 results in degradation of ERα and, conse-
quently, elevated expression of genes typically repressed by
ERα. Indeed, treatment of sh-Control MCF7 and T-47D
cells caused degradation of ERα with a concomitant increase
in TP63 (Fig. 6e). Interestingly, ICI-182,780 treatment did
not have an effect on EGFR but reduced the level of TP63
in sh-UNC5A cells (Fig. 6e). Similar to TP63, elevated ex-
pression of BCL2 upon UNC5A knockdown is ERα-
dependent as its levels were lower in ICI-182,780-treated
cells compared with untreated sh-UNC5A cells (Fig. 6e).
Thus, while elevated EGFR levels in sh-UNC5A cells are
ERα-independent, ΔNp63 and BCL2 upregulation in these
cells is at least partially ERα-dependent.
sh-UNC5A cells form metastatic tumors independent of E2
supplementation
MCF7 cells form nonmetastatic tumors in female nude
mice when injected with matrigel or when supplementedwith E2 pellets, although there is less uniformity between
the sizes of tumors between animals [16]. We had previ-
ously reported in the MDA-MB-231 model that cell lines
derived from tumors that develop in the mammary fat
pad upon implantation of parental cells show enhanced
and uniform tumorigenicity upon re-implantation [50].
We used this approach to increase uniformity in tumori-
genicity and generated TMCF7 sh-Control, sh2-UNC5A,
and sh5-UNC5A cells. As with MCF7 cells, sh-UNC5A
TMCF7 cells showed elevated BCL2 and ΔNp63 com-
pared with sh-Control cells (Additional file 8). sh-UNC5A
but not sh-Control TMCF7 cells displayed KRT14/KRT19
double-positive phenotype (Additional file 8). A large sub-
population of sh-UNC5A TMCF7 cells was of the CD44+/
CD24+ and CD49f+/EPCAM+ phenotype compared with
sh-Control cells (Additional file 8), and mammospheres
formed by these cells were irregular compared to
mammospheres from sh-Control cells (Additional file 8).
In addition, sh-UNC5A TMCF7 cells expressed significantly
higher levels of SOX2 despite maintaining ERα
expression (Additional file 8). Consistent with RNA-seq
data (Additional file 6), a large subpopulation of sh-UNC5A
TMCF7 cells were ITGB6+ compared with sh-Control cells
(Additional file 8).
A significant number of mice injected with sh-UNC5A
cells but not sh-Control cells developed tumors in the
absence of E2 pellets (Fig. 7a). The size of these tumors
was larger than tumors in animals injected with sh-
Control cells in the presence of E2 pellet (Fig. 7b).
While none of the animals injected with sh-Control cells
developed lung metastasis, consistent with our previous
study with TMCF7 cells [16], animals that received
sh-UNC5A cells showed lung metastasis (Fig. 7c). We
next examined whether sh-Control cell- and sh-UNC5A
cell-derived tumors differ in angiogenesis because of the
differences in NTN4 expression between sh-Control and
sh-UNC5A cells noted in Fig. 5. sh-UNC5A cell-derived
tumors contained higher numbers of PECAM1+ cells
compared with sh-Control cell-derived tumors (Fig. 7d),
suggesting enhanced angiogenesis in the absence of
UNC5A.
Fig. 6 UNC5A knockdown results in elevated epidermal growth factor receptor (EGFR) and phospho-AKT. a EGFR protein levels in sh-Control and
sh-UNC5A TMCF7 and T-47D cells. b Phospho-AKT and phospho-ERK levels in sh-Control and sh-UNC5A TMCF7 cells with or without estradiol (E2)
or HRG-β1 (20 ng/ml) treatment. Cells were treated with vehicle, E2 for 5 and 15 min, and HRG-β1 for 15 min. c Phospho-AKT1 and phospho-AKT2 levels
in sh-Control and sh-UNC5A TMCF7 cells. d Representative EGFR staining pattern in breast tumors with low or high expression (left, scale bar = 100 μm).
Summary of the correlation analysis between EGFR and UNC5A from breast cancer TMA using Spearman’s correlation coefficient (right). UNC5A and EGFR
expression was inversely correlated (p< 0.001, n= 179). e Protein levels of estrogen receptor (ER)α, EGFR, BCL2, and TP63 in sh-Control and sh-UNC5A
TMCF7 (left) and T-47D (right) cells after treatment with ICI-182,780 (Fulvestrant)
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the multiorgan homing capacity of tumor cells, sh-Control
and sh-UNC5A cells were injected via the intracardiac
route into animals supplemented with E2 pellets. Autop-
sies within 17 weeks of injection revealed growth of tumor
cells in ovaries and adrenal glands at a higher frequency in
animals injected with sh-UNC5A cells compared with sh-
Control cells (Fig. 7e). Histological analysis revealed asevere disruption of the normal architecture of both or-
gans (Fig. 7f). Ovaries were devoid of follicles and corpora
lutea, and the very few remaining were undergoing atresia
and degeneration. Likewise, adrenals lost a clear differenti-
ation between the cortex and medulla zones with
hemorrhagic areas and high vacuolization even in areas
where the capsule is still preserved. Spleens of animals
that received sh-UNC5A cells showed extramedullary
Fig. 7 (See legend on next page.)
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Fig. 7 UNC5A knockdown cells form tumors independent of E2 supplementation. a The number of animals with tumors after injection of sh-Control,
sh2- and sh5-UNC5A TMCF7 cells in the absence of implanted estradiol (E2) pellet. Number of sh2-UNC5A (p < 0.05) and sh5-UNC5A (p < 0.001) mammary
fat pad tumor-positive mice at the time of euthanasia (11 weeks postinjection). b Tumor volume in animals injected with sh-Control, sh2-UNC5A, or
sh5-UNC5A TMCF7 cells with or without E2 pellets (mean ± SEM). c Lung metastasis pattern in animals injected with sh-Control or sh-UNC5A cells into the
mammary fat pad in the presence of implanted E2 pellets. The number of animals with and without lung metastasis is shown on the left (p < 0.05),
whereas representative lung sections stained with hematoxylin and eosin (H&E) from sh-Control, sh2-, and sh5-UNC5A TMCF7 cell inoculated mice with
an E2 pellet is shown on the right. Arrowheads point to metastatic tumor cells (al, alveolus; scale bar = 200 μm). Data were analyzed using the Fisher’s
exact test (two-tailed). Lungs from only three sh-Control cell injected animals were examined because we had previously shown a lack of lung metastasis
in animals injected with TMCF7 cells [16]. d sh-UNC5A TMCF7 cell-derived tumors show significant levels of angiogenesis. PECAM1 staining was performed
to measure endothelial cells in tumors. The number of PECAM1+ cells in at least 12 fields per tumor is shown on the left, whereas representative
PECAM1 staining pattern is shown on the right (scale bar = 200 μm; *p < 0.05 and ***p < 0.001). e UNC5A knockdown cells show enhanced metastases
to ovaries and adrenal glands. The number of animals with metastases to ovaries and adrenal glands is shown on the left, whereas the gross
appearance of ovaries and adrenal glands of sh-UNC5A TMCF7 cells injected via the intracardiac route and the H&E staining pattern of ovary and
adrenal gland with metastasis are shown on the right. Scale bars = 3 mm and 200 μm. f Model depicting crosstalk between UNC5A, epidermal growth
factor receptor (EGFR), and E2 signaling. Unliganded UNC5A likely inhibits E2 signaling, which may be reversed upon binding of NTN1. Question marks
indicates unknown mechanisms of regulation. ER, estrogen receptor
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ments and megakaryocytes causing distention of the
spleen in the red pulp area (data not shown). Overall, the
results presented above clearly indicate the role of
UNC5A in regulating the metastasis of ER+ tumors and
its loss of expression leading to E2-independent growth
both in vitro and in vivo.
Discussion
UNC5A is a transmembrane receptor that generates cell
survival or death signals in a ligand-dependent manner
[10]. UNC5A and NTN1 are described as tumor
suppressor and oncogene, respectively, in breast cancer
[51, 52]. However, signaling pathways that control their
expression to alter the balance between UNC5A and
NTN1 are unknown. Analyses of TCGA dataset showed
elevated expression of UNC5A in luminal breast cancers,
and NTN1 overexpression in TNBCs and E2 could fur-
ther enhance luminal expression of UNC5A (Fig. 1).
Thus, the UNC5A–NTN1 signaling axis is likely tilted
more towards UNC5A-activated signals in ERα+/PR+
breast cancers and NTN1-generated signals in TNBC/
ER− tumors. Consistent with this possibility, UNC5A
expression was prognostic in ER+/PR+/HER2− breast
cancers but not in ER− tumors, suggesting its critical
role in ER+/PR+/HER2− breast cancers. A subgroup of
women with ER+/PR+ breast cancers develop recurrence,
and molecular assays such as the Recurrence Score and
Breast Cancer Index are helping to identify ER+/PR+
breast cancer patients requiring hormonal and/or
chemotherapy [53]. UNC5A, possibly in combination
with EGFR, could be developed as a biomarker to
identify such patients [4].
Molecular events causing variable UNC5A expression
in ER+ tumors are unknown. UNC5A is a TP53-
inducible gene, and TP53 is infrequently mutated in
ER+/PR+ breast cancer [2, 54]. Deregulated p53 activity
instead of mutations may lead to loss of UNC5Aexpression in ER+/PR+ tumors, although this remains to
be investigated. In addition, there is potential for p53 to
control UNC5A activity since we noted a differential
effect of UNC5A knockdown on proliferation in wild-
type p53 containing MCF7 cells compared with mutant
p53 containing T-47D cells, although knockdown had a
similar effect on BCL2 and TP63 expression in both cell
lines. cBioPortal analyses revealed frequent missense and
truncating mutations in UNC5A [55]. Additionally,
UNC5A expression is regulated through allele-specific
DNA methylation [56]. Thus, mutations and DNA methy-
lation could be other mechanisms leading to inactivation/
silencing of UNC5A during breast cancer progression.
One of the consequences of reduced UNC5A expres-
sion is significant changes in basal gene expression and
altered ERα signaling. GO analyses revealed a specific
effect of UNC5A knockdown on a network of transcrip-
tion factors including the stem cell-associated transcrip-
tion factor SOX2, which may be a reason for the altered
expression of 20% of genes in sh-UNC5A MCF7 cells
and 7% in sh-UNC5A T-47D cells compared with sh-
Control cells (Fig. 4). It is interesting that, in both cell
lines, UNC5A knockdown affected the expression of
genes linked to the plasma membrane and extracellular
region composition (Fig. 4), which can explain the ag-
gressive growth characteristics of sh-UNC5A compared
with sh-Control MCF7 cells in vivo. We also observed a
distinct effect of UNC5A on E2-regulated gene expres-
sion, with several genes gaining E2-regulated gene ex-
pression (Fig. 4). These results suggest a role for
UNC5A in restricting the activity of unliganded ERα in a
gene-specific manner, which could involve the following
mechanisms. One possibility is the direct effect of
UNC5A-activated signals on chromatin organization
since we observed an effect of UNC5A knockdown on
the histone demethylation network in E2-treated cells
(Fig. 4). UNC5A knockdown increased the E2-inducible
expression of KDM4B, which is a master regulator of
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could further amplify the E2 signaling axis as evident
from more than 400 genes gaining E2-regulated expres-
sion in sh-UNC5A cells. Robustness at which UNC5A
knockdown altered BCL2 expression further suggests a
direct link between UNC5A and chromatin organization.
This drastic effect of UNC5A knockdown on BCL2 ex-
pression is reminiscent of permanent gene expression
changes observed upon transient knockdown of DNMT1
[38]. However, we did not observe an effect of UNC5A
knockdown on the expression of any DNMTs, although
there was a modest but statistically significant effect on
TET1 and TET3 which antagonize DNMTs (Additional
file 6). UNC5A knockdown may have an effect on his-
tone acetylation/deacetylation since sh-UNC5A MCF7
cells expressed significantly higher levels of the epigen-
etic regulator HDAC9 compared with sh-Control cells
(Additional files 6). The second possibility is the involve-
ment of ELF5. ELF5 suppresses E2 sensitivity by redu-
cing the expression of ESR1 and the pioneer factors
FOXA1 and GATA3 [36]. ERα, FOXA1, and GATA3
constitute a positive lineage-restricted hormone respon-
sive regulatory loop in luminal cells [58]. We observed
the effect of UNC5A knockdown on ELF5 expression,
and reduced ELF5 expression in sh-UNC5A MCF7 cells
correlated with elevated GATA3 expression (Additional
file 6). The third possibility is the involvement of AKT.
UNC5A knockdown caused upregulation of activated
AKT, which confers ligand-independent activity to ERα
[59]. The fourth possibility involves ERα–EGFR cross-
talk since UNC5A knockdown cells contained higher
levels of EGFR protein (Fig. 7), and EGF through EGFR
has been shown to alter ERα cistrome and transcrip-
tome [60].
UNC5A knockdown in MCF7 cells resulted in a hybrid
phenotype with cells expressing luminal (ER, PGR),
myoepithelial (TP63), and stem cell markers (SOX2),
which in part is due to altered ERα signaling. Recent
studies have identified similar hybrid cells in primary
breast cancers, potentially generated through Notch-
Jagged signaling [42, 61]. Based on cell surface marker
profiles and KRT14/KRT19 expression patterns in sh-
UNC5A cells, we propose that the gradual loss of
UNC5A results in cancer cells acquiring hybrid pheno-
type without expressing classic markers of EMT. Since
there is still a controversy related to in-vivo detection of
cancer cells with EMT features, it is possible that pri-
mary tumors contain cells with hybrid phenotype which
functionally behave like cancer cells with EMT features.
Characterizing primary tumors for ER, PR, UNC5A,
EGFR, and additional basal cell markers would allow the
detection of such hybrid cells. Collectively, results pre-
sented in this study provide novel insights into pathways
that restrict ERα signaling and metastatic progression ofERα+ breast cancer, which potentially involves luminal
to luminal/basal hybrid conversion due to an aberrant
DR pathway.Conclusions
In this study, we demonstrate an unexpected role for the
dependence receptor UNC5A in regulating ERα activity
and restricting the expression of basal cell-enriched
genes in luminal cells. Progressive loss of UNC5A
expression could result in ERα-positive luminal cells
acquiring basal features including the expression of
ΔNp63, SOX2, and EGFR, while maintaining ERα ex-
pression. These results describe the role of UNC5A in
controlling plasticity of luminal breast cancer. Therefore,
UNC5A, ERα, and EGFR could be developed as markers
to identify luminal breast cancers with a potential for
subtype conversion.Additional files
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